Catalyst Pharmaceuticals reports $4.9M loss for Q1 2017

Catalyst Pharmaceuticals has reported a GAAP net loss of $4.9 million for first quarter of 2017, compared to a GAAP net loss of $5,4 for the same period in 2016.

Patrick J. McEnany, Chief Executive Officer of Catalyst commented: “We continue to work diligently toward the completion of enrollment in our Firdapse LEMS and CMS clinical trials.”

McEnany also announced positive top-line results from a proof-of-concept trial for Firdapse as a potential treatment for myasthenia gravis patients that are MuSK antibody positive.

McEnany added: “We remain committed to the rest of our scientific pipeline and continue to seek ways to leverage our CPP-115 and vigabatrin programs.”